Marco Meglio

In the original panel discussion, held in March 2022, the majority of members of the committee voted that AMX0035 did not fully demonstrate sufficient efficacy as a treatment for ALS.

The chair of Cleveland Clinic’s Department of Physical Medicine discussed a new rehabilitative approach using a robotic exoskeleton to improve fatigue and gait in patients with multiple sclerosis.

All 12 of the children met diagnostic criteria for multiple sclerosis and were seropositive for MOG-IgG at baseline experienced a disease course different than typical MS through the observed time.

Alectos to receive a $15 million upfront payment from Biogen and is eligible to receive upward of $630 million pending the success of the collaboration and achieving future milestones for the investigational PD treatment.

Using a large-scale bank of participants, investigators found an association between Alzheimer disease polygenetic risk score and depression, which was not explained by presence of APOE ε4 allele.

Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.

In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.

Despite not reaching the primary end point, the oromucosal spray is still being evaluated in 2 ongoing trials that comprise of 446 and 190 patients, respectively, with spasticity due to multiple sclerosis.

Patients with high levels of neurofilament light at baseline had an increased risk of developing new T2 lesions and of experiencing a new clinical relapse in the follow-up period, but not of EDSS progression.

Following positive phase 2a findings, NeuroSense’s agent PrimeC continued to show a mechanistic impact on biomarkers specific to patients with amyotrophic lateral sclerosis.

Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.

The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed a recent study on a new tool aimed at quantifying movements during stroke rehabilitation.

Over a 12-week treatment period, brexpiprazole demonstrated statistically significant improvements on the primary and secondary end points compared with placebo.

Ocrelizumab (Ocrevus; Genentech), an anti-CD20 treatment FDA-approved for progressive MS, was shown to reduce thalamic volume loss, with even greater outcomes when initiated earlier.

During months 36 and 48 on open-label cenobamate treatment, 76.4% and 51.8% of patients achieved seizure reductions of at least 50% or 75%, respectively.

In total, 100% and 93% of those in the SMN two- and three-copy cohorts achieved the primary end point of sitting independently for at least 30 seconds after 18 months of treatment.

Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.

BIIB122, a selective central nervous system-penetrant small molecule inhibitor of LRRK2 is expected to be evaluated in a cohort of 640 patients with early-stage Parkinson disease.

At least 2 weeks following Evusheld injection, all 18 patients included in the cohort had the highest level of antibody response.

The decision to stop clinical testing of SRP-5051 in DMD follows a serious adverse event of hypomagnesemia in part B of the phase 2 MOMENTUM trial.

Based on the 35-week interim trial results, AstraZeneca and Ionis will seek regulatory approval for eplontersen and plan to file a new drug application with the FDA in 2022.

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

Both the early- and delayed-start tofersen treatment groups demonstrated reductions in SOD1 protein, the intended target for tofersen, and neurofilament, a marker of axonal injury and neurodegeneration.

Originally approved for the preventive treatment of episodic migraine in Sept 2021, atogepant’s potential new indication stems from positive results from the double-blind, placebo-controlled, phase 3 PROGRESS trial.

Over an 18-month treatment period, patients with prodromal to mild Alzheimer disease demonstrated similar increases in Clinical Dementia Rating-Sum of Boxes scores regardless of treatment with placebo or semorinemab.

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.

Endovascular therapy with alteplase was associated with lower morality, home discharge destination, greater likelihood to have no major disability, and ability to ambulate at discharge.

Through the StrivePD ecosystem and an Apple Watch, patients, including those who have been treated with Medtronics’ deep brain stimulation device, are able to track and log their symptoms.

After 24 weeks of treatment, the adjusted mean annualized relapse rates were 0.53 with placebo vs 0.39 and 0.48 for the 30- and 45-mg groups of IMU-838.

In the first NIH-backed study to evaluate an experimental prevention therapy in cognitively unimpaired persons at risk for Alzheimer disease, crenezumab showed small numerical, but not statistically significant differences compared with placebo.